Monopar Therapeutics (MNPR) stock
MNPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$71.97−0.03 (-0.04%)
Close on Nov 16, 2026Market cap $483.08MP/E –Yield –
Monopar Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Monopar Therapeutics's enterprise value was $376.09M on Nov 11, 2026, against $319.04M a year earlier. Over the last 5 years it ranged from -$10.35M to $645.92M, with a median of $18.72M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $376.09M | +109.0% |
| 2025 | Dec 31, 2025 | $179.92M | +173.7% |
| 2024 | Dec 31, 2024 | $65.74M | – |
| 2023 | Dec 29, 2023 | -$8.34M | -151.6% |
| 2022 | Dec 30, 2022 | $16.15M | -10.6% |
| 2021 | Dec 31, 2021 | $18.07M | -65.3% |
| 2020 | Dec 31, 2020 | $52.10M | -65.2% |
| 2019 | Dec 31, 2019 | $149.74M | – |
See a number that looks wrong?